Allosteric modulation of G-protein-coupled receptors

Bibliography

• MONOD J, CHANGEUX J-P, JACOB F: Allosteric proteins and cellular control systems. j Mel Biol. (1963) 6:306–329.
   PubMed Web of Science ®Google Scholar
• DREWS J: Drug discovery: a historical perspective. Science (2000) 287:1960–1964.
   PubMed Web of Science ®Google Scholar
• SCHONEBERT T, SCHULTZ G, GUDERMANN T: Structural basis of G protein-coupled receptor function. Mel Cell Endocrine]. (1999) 151:181–193.
   PubMed Web of Science ®Google Scholar
• LAZARENO S, GHARAGOZLOO P, KUONEN D, POPHAM A, BIRDSALL NJ: Subtype-selective positive cooperative interactions between brucine analogues and acetylcholine at muscarinic receptors: radioligand binding studies. Mel Pharmacy]. (1998) 53:573–89.
   PubMed Web of Science ®Google Scholar
• FAWZI AB, MACDONALD D, BENBOW LL etal.: SCH-202676: an allosteric modulator of both agonist and antagonist binding to G protein-coupled receptors. Mel Pharrnacol. (2001) 59:30–37.
   Google Scholar
• BIRDSALL NJM, FARRIES T, GHARAGOZLOO E KOBAYASHI S, LAZARENO S, SUGIMOTO M: Subtype-selective positive cooperative interactions between brucine analogs and acetylcholine at muscarinic receptors: functional studies. Mel. Pharrnacel (1999) 55:778–786.
   PubMed Web of Science ®Google Scholar
• •This study shows that allosteric enhancers of muscarinic receptors can be active in intact tissues.
   Google Scholar
• LAZARENO S, POPHAM A, BIRDSALL NJM: Allosteric interaction of staurosporine and other indolocarbazoles with N- [methyl-3H1 scopolamine and acetylcholine at muscarinic receptor subtypes: identification of a second allosteric site. j Pharrnacol. Exp. Expert Op/n. Ther. Patents (2001) 11(12)1901 Ther. (2000) 58:194–207.
   Google Scholar
• JAKUBIK J, BACAKOVA L, EL-FAKAHANY EE, TUCEK S: Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mal Pharmacol. (1997) 52:172–179.
   PubMed Web of Science ®Google Scholar
• TRANKLE C, MIES-KLOMFASS E, BOTERO CID MH, HOLZGRABE U, MOHR K: Identification of a PFIlligand for the common allosteric site of muscarinic acetylcholine M2 receptors. Mal Pharmacol. (1998) 54:139–145.
   PubMed Web of Science ®Google Scholar
• •In this paper the first useful radioligand interacting with an allosteric site is described.
   Google Scholar
• BOTERO CID HM, TRANKLE C, BAUMANN K et al.: Structure-activity relationships in a series of bisquaternary bisphthalimidine derivatives modulating the muscarinic M2-receptor allosterically. Med.Chem. (2000) 43:2155–2164.
   Web of Science ®Google Scholar
• BENDER W, STAUDT M, TRANKLE C, MOHR K, HOLZGRABE U: Probing the size of a hydrophobic binding pocket within the allosteric site of muscarinic acetylcholine M2-receptors: unilateral variation of alkane bisammonium-type ligands. Life Li. (2000) 66:1675–1682.
   Google Scholar
• DOCHERTY JR: Subtypes of functional al- and a2-adrenoceptors. Eur. Pharmacol (1998) 361:1–15.
   PubMed Web of Science ®Google Scholar
• ZHONG H, MINNEMAN KP: al-adrenoceptor subtypes. Eur. j Pharmacol (1999) 375:216–276.
   Web of Science ®Google Scholar
• LEPPIK RA, MYNETT A, LAZARENO S, BIRDSALL NJM: Allosteric interactions between the antagonist prazosin and amiloride analogues at the human alp-adrenergic receptor. Mal Pharmacol (2000) 57:436–445
   PubMed Web of Science ®Google Scholar
• WAUGH DJJ, GAIVIN RJ, DAMRON DS, MURRAY PA, PEREZ DM: Binding, partial agonism and potentation of al-adrenergic receptor function by benzodiazepines: a potential site of allosteric modulation. j Pharmacol Esp. Ther. (1999) 291:1164–1171.
   PubMed Web of Science ®Google Scholar
• KABLE JW, MURRIN LC, BYLUND DB:In vivo gene modification elucidates subtype-specific functions of a2-adrenergic receptors. j Pharmacol Exp. Ther. (2000) 293:1–7.
   PubMed Web of Science ®Google Scholar
• LEPPIK RA, LAZARENO S, MYNETT A,BIRDSALL NJ: Characterization of the allosteric interactions between antagonists and amiloride analogues at the human a2A- adrenergic receptor. Mal Pharmacol (1998) 53:916–925.
   PubMed Web of Science ®Google Scholar
• LEPPIK RA, BIRDSALL NJM: Agonist binding and function at the human a2A adrenoceptor: allosteric modulation by amilorides. Mal Pharmacol (2000) 58:1091–1099.
   PubMed Web of Science ®Google Scholar
• MOLDERINGS GJ, MENZEL S, KATHMANN M, SCHLICKER E, GOTHERT M: Dual interaction of agmatine with the rat a2-adrenoceptor: competitive antagonism and allosteric activation. Br. j Pharmacol (2000) 130:1706–1712.
   PubMed Web of Science ®Google Scholar
• ROUSSELLE JC, MASSOT 0, DELEPIERRE M, ZIFA E, ROUSSEAU B, FILLION G: Isolation and characterization of an endogenous peptide from rat brain interacting specifically with the serotonergic 1B receptor subtypes. I Biol. Chem. (1996) 271:726–735.
   Web of Science ®Google Scholar
• •First report to show the unusual and high activity of 5-HT-moduline.
   Google Scholar
• MASSOT 0, ROUSSELLE JC, FILLION MP et al: 5-Hydroxytryptamine-moduline, a new endogenous cerebral peptide controls the serotonergic activity via its interaction with 5-hydroxytryptamine 1B/1D receptors. Mal Pharmacol (1996) 50:752–762.
   PubMed Web of Science ®Google Scholar
• ROUSSELLE JC, PLANTEFOL M, FILLION MP, MASSOT 0, PAUWELS PJ, FILLION G: Specific interaction with of 5-HT-moduline with human 5-HT1B as well as 5-HT1D receptors expressed in transfected cultured cells. NS Arch. Pharmacol (1998) 358:279–286.
   PubMed Web of Science ®Google Scholar
• GRIMALDI B, FILLION MP, BONNIN A, ROUSSELLE JC, MASSOT 0, FILLION G: Immunocytochemical localization of neurons expressing 5-HT-moduline in mouse brain. Neuropharmacol (1997) 36:1079–1087.
   PubMed Web of Science ®Google Scholar
• PLANTEFOL M, ROUSELLE J-P, BERNARDI E, SCHOOFS AR, POURRIAS B, FILLION G: Endoproteolytic activity in mammalian brain membranes cleaves 5-hydroxytryptamine - moduline into dipeptides. Eur. Pharmacol (1999) 376:109–117.
   PubMed Web of Science ®Google Scholar
• BONNIN A, GRIMALDI B, FILLION MP, FILLION G: Acute stress induces a differential increase of 5-HT moduline (LSAL) tissue content in various rat brain areas. Brain Res. (1999) 825:152–160.
   PubMed Web of Science ®Google Scholar
• GRIMALDI B, BONNIN A, FILLION MP, PRUDHOMME N, FILLION G: 5- Hydroxytryptamine-moduline: a novel endogenous peptide involved in the control of anxiety. Neuroscience (1999) 93:1223–1225.
   PubMed Web of Science ®Google Scholar
• MORET CH, BRILEY M: The possible role of 5-HT1B/D receptors in psychiatric disorders and their potential as a target for therapy. Eur. I Pharmacol (2000) 404:1–12.
   PubMed Web of Science ®Google Scholar
• GRIMALDI B, FILLION G: 5-HT-moduline controls serotonergic activity: implication in neuroimmune reciprocal regulation mechanisms. Progress Neurobiology (2000) 60:1–12.
   PubMed Web of Science ®Google Scholar
• HUIDOBRO-TURO JP, HARRIS RA: Brain lipids that induce sleep are novel modulators of 5-hydroxytryptamine receptors. Proc. Natl. Acad. Sci. USA (1996) 93:8078–8082.
   PubMed Web of Science ®Google Scholar
• •Evidence for the existence of endogenous allosteric modulators of GPCR function.
   Google Scholar
• BOGER DL, PATTERSON JE, JIN Q: Structural requirements for 5-HT 2A and 5-HT1A serotonin receptor potentiation by the biological active lipid oleamide. Proc. Natl. Acad. Sci. USA (1998) 95:4102–4107.
   PubMed Web of Science ®Google Scholar
• THOMAS EA, CARSON MJ, SUTCLIFFE JG: Oleamide-induced modulation of 5-hydroxytryptamine receptor mediated signalling. Annals NY Acad. Sci (1998) 861:183–189.
   PubMed Web of Science ®Google Scholar
• HEDLUND PB, CARSON MJ, SUTCLIFFE JG, THOMAS EA: Allosteric regulation by oleamide of the binding properties of 5-hydroxytryptamine7 receptors. Biochem. Pharmacol (1999) 58:1807–1813.
   PubMed Web of Science ®Google Scholar
• HOARE SRJ, COLDWELL MC, ARMSTRONG D, STRANGE PG: Regulation of human D1, D2 (long), D2 (short), D3 and D4 dopamine receptors by amiloride and amiloride analogues. Br Pharmacol (2000) 130:1045–1059.
   PubMed Web of Science ®Google Scholar
• SCHETZ JA, SIBLEY DR: The binding-site crevice of the D4 dopamine receptor is coupled to three distinct sites of allosteric modulation. I Pharmacol Exp. Ther. (2001) 296:359–363.
   PubMed Web of Science ®Google Scholar
• BAURES PW, OJALA WH, COSTAIN WJ: Design, synthesis and dopamine receptor modulating activity of diketopiperazine peptidomimetics of L-prolyl-L-leucylglycinamide. I Med. Chem (1997) 40:3594–3600.
   PubMed Web of Science ®Google Scholar
• •Peptides that have potent allosteric actions on dopamine receptors.
   Google Scholar
• BAURES PW, PRADHANA A, OJALA WH, GLEASON WB, MISHRA RK, JOHNSON RL: Synthesis and dopamine modulation activity of unsubstituted and substituted triproline analogues of L-prolyl-L-leucylglycinamide (PLG). Bioorg. Med. Chem. Lett. (1999) 9:2349–2352.
   PubMed Web of Science ®Google Scholar
• RALEVIC V, BURNSTOCK G: Receptors for purines and pyrimidines. Pharmacol. Rev (1998) 50:413–492.
   PubMed Web of Science ®Google Scholar
• LINDEN J: Allosteric enhancement of adenosine receptors. In: Purinergic approaches in experimental therapeutics. Jacobson KA, Jarvis NF (Eds.), Wiley-Liss, Inc., New York, NY, USA (1997).
   Google Scholar
• BRUNS RF, FERGUS JH: Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes. Mol. Pharmacol. (1990) 38 :939–949.
   PubMed Web of Science ®Google Scholar
• •Seminal paper with data on PD81,723.
   Google Scholar
• MIZUMURA T, AUCHAMPACH A, LINDEN J, BRUNS RE GROSS GJ: PD81,723, an allosteric enhancer of the A1 adenosine receptor, lowers the threshold for ischemic preconditioning in dogs. Circ. Res. (1996) 79:415–423.
   PubMed Web of Science ®Google Scholar
• BRUNS RE FERGUSON JH, COUGHENOUR LL et al.: Structure-activity relationships for enhancement of adenosine A1 receptor binding by 2-amino-3-benzoylthiophenes. Mol. Pharmacol. (1990) 38:950–958.
   PubMed Web of Science ®Google Scholar
• JARVIS ME GESSNER G, SHAPIRO G et al.: Differential effects of the adenosine A1 receptor allosteric enhancer PD 81,723 on agonist binding to brain and adipocyte membranes. Brain Res. (1999) 840:75–83.
   PubMed Web of Science ®Google Scholar
• KOLLIAS-BAKER C, RUBLE J, DENNIS D, BRUNS RF, LINDEN J, BELARDINELLI L: Allosteric enhancer PD 81,723 acts by novel mechanism to potentiate cardiac actions of adenosine. Circ. Res. (1994) 75:961–971.
   PubMed Web of Science ®Google Scholar
• JANUSZ CA, BRUNS RE BERMAN RF: Functional activity of the adenosine binding enhancer, PD 81,723, in the in vitro hippocampal slice. Brain Res. (1991) 567:181–187.
   PubMed Web of Science ®Google Scholar
• MUDUMBI RV, MONTAMAT SC, BRUNS RE VESTAL RE: Cardiac functional responses to adenosine by PD 81,723, an allosteric enhancer of the adenosine A1 receptor. Am. j Physiol. (1993) 264:H1017–22.
   PubMed Web of Science ®Google Scholar
• PHILLIS JW, SMITH BARBOUR M, PERKINS LM, O'REGAN MH: Characterization of glutamate, aspartate and GABA release from ischemic rat cerebral cortex. Brain Res. Bull. (1994) 34:457–466.
   PubMed Web of Science ®Google Scholar
• KOLLIAS-BAKER C, XU J, PELLEG A,BELARDINELLI L: Novel approach for enhancing atrioventricular nodal conduction delay mediated by endogenous adenosine. Circ. Res. (1994) 75:972–980.
   PubMed Web of Science ®Google Scholar
• MUSSER B, MUMDUMBI RV, LIU J, OLSON RD, VESTAL RE: Adenosine A1 receptor - dependent and - independent effects of the allosteric enhancer PD 81,723. Pharmacol. Exp. Ther. (1999) 288:446–454.
   PubMed Web of Science ®Google Scholar
• BATTACHARYA S, LINDEN J: Effects oflong-term treatment with the allosteric enhancer, PD 81,723, on Chinese hamster ovary cells expressing recombinant human A1 adenosine receptors. Mol. Pharmacol. (1996) 50:104–111.
   PubMed Web of Science ®Google Scholar
• BHATTACHARYA S, LINDEN J: The allosteric enhancer, PD 81,1723, stabilizes human A1 adenosine receptor coupling to G proteins. Biochem. Biophys. Acta Mol. Cell. Res. (1995) 1265:15–21.
   PubMed Web of Science ®Google Scholar
• VAN DER KLEIN PA, KOUROUNAKIS AF IJZERMAN AP: Allosteric modulation of the adenosine A1 receptor. Synthesis and biological evaluation of novel 2-amino-3-benzoylthiophenes as allosteric enhancers of agonist binding. I Med. Chem. (1999) 42:3629–3635.
   Google Scholar
• GAO ZG, UZERIVIAN AP: Allosteric modulation of A2A receptors by amiloride analogues and sodium ions. Biochem. Pharmacol. (2000) 60:669–676.
   PubMed Web of Science ®Google Scholar
• SHIOZAKI S, ICHIKAWA S, NAKAMURA J, KITAMURA S, YAMADA K, KUWANA Y: Actions of adenosine A2A receptor antagonist HW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology (1999) 147:90–95.
   PubMed Web of Science ®Google Scholar
• LITSCHIG S, GASPARINI E RUEEGG D: CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. Mol. Pharmacol. (1999) 55:453–461.
   PubMed Web of Science ®Google Scholar
• GASPARINI E LINGENH_HL K, STOEHR N et al.: 2-methyl-6-(phenylethyny1)-pyridine (MPEP) a potent selective and systemically active mglu 5 receptor antagonist. Neuropharmacology (1999) 38:1493–1503.
   Google Scholar
• PAGANO A, R_EGG D, LITSCHIG S et al.: The non-competitive antagonists 2-methyl- 6-(phenylethynyOpyridine and 7-hydroxyiminocyclopropan lb] chromen-1a-carboxylic acid ethylester interact with overlapping binding pockets in the transmembrane region of group I metabotropic glutamate receptors. _J. Biol. Chem. (2000) 275:33750–33758.
   Google Scholar
• SPOOREN WJPM, GASPARINI E SALT THE, KUHN R: Novel allosteric antagonists shed light on mglu 5 receptors and CNS disorders. Trends Pharmacol. Sci. (2001) 22:331–337.
   PubMed Web of Science ®Google Scholar
• •Fine summary of non-competitive antagonists of metabotropic glutamate receptor function.
   Google Scholar
• WADA M, NAGANO N, NEMETH EF: The calcium receptor and calcimimetics. Cun: Opin. Nephrol. Hypertens. (1999) 8:429–433.
   PubMed Web of Science ®Google Scholar
• CONIGRAVE AD, QUINN SJ, BROWN EM: Cooperative multi-modal sensing and therapeutic implications of the extracellular Ca2+-sensing receptor. Trends Pharmacol. Sri. (2000) 21:401–407.
   PubMed Web of Science ®Google Scholar
• NEMETH EF, STEFFEY ME, HAMMERLAND LG et al.: Calcimimetics with potent and selective activity on parathyroid calcium receptor. Proc. Nati Acad. Sci. USA (1998) 95:4040–4045.
   PubMed Web of Science ®Google Scholar
• •First disclosure of calcimimetics acting via allosteric mechanisms.
   Google Scholar
• FOX J, LOWE SH, PETTY BA, NEMETH EF: NPS R-568: a typeII calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium. j Pharmacol. Exp. Ther. (1999) 290:473–479.
   PubMed Web of Science ®Google Scholar
• FOX J, LOWE SH, CONKLIN RL, PETTY BA, NEMETH EF: Calcimimetic compound NPS R-568 stimulates calcitonin secretion but selectively targets parathyroid gland Ca2+ receptors in rats. Pharmacol. Exp. Ther. (1999) 290:480–486.
   PubMed Web of Science ®Google Scholar
• GOWEN M, STROUP GB, DODDS RA et al.: Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J. Clin. Invest. (2000) 105:1595–1604.
   PubMed Web of Science ®Google Scholar
• CONIGRAVE AD, QUINN SJ, BROWN EM: L-Amino acid sensing by the extracellular Ca2±-sensing receptor. Proc. Natl. Acad. Sci. USA (2000) 97:4814–4819.
   PubMed Web of Science ®Google Scholar